
J.P. Morgan analyst Tessa Romero has maintained their bullish stance on LXEO stock, giving a Buy rating yesterday. Tessa Romero’s rating is based on several factors, including encouraging interim results
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| LXEO | Lexeo Therapeutics, Inc. | 2.86 | -5.52 | -65.93% |
| Name | Price | % Change | |
|---|---|---|---|
| $2.86 | -65.93% |

J.P. Morgan analyst Tessa Romero has maintained their bullish stance on LXEO stock, giving a Buy rating yesterday. Tessa Romero’s rating is based on several factors, including encouraging interim results

Lexeo Therapeutics, Inc. (LXEO) has disclosed a new risk, in the Corporate Activity and Growth category. Lexeo Therapeutics, Inc. faces material risk that its pursuit of acquisitions, licenses, disposals, and

Raymond James analyst Christopher Raymond has maintained their bullish stance on LXEO stock, giving a Buy rating today. Christopher Raymond’s rating is based on several factors, led by LX2020’s substantially

Raymond James raised the firm’s price target on Lexeo Therapeutics (LXEO) to $42 from $24 and keeps a Strong Buy rating on the shares. The LX2020 12-month data showed substantial

Cantor Fitzgerald raised the firm’s price target on Lexeo Therapeutics (LXEO) to $37 from $23 and keeps an Overweight rating on the shares. Lexeo reported Phase 1/2 interim data for

Lexeo Therapeutics, Inc. ( ($LXEO) ) has provided an update. On November 16, 2026, Lexeo reported interim HEROIC-PKP2 Phase I/II data from 10 participants evaluating LX2020 for PKP2-associated arrhythmogenic cardiomyopathy.

Lexeo Therapeutics (LXEO) announced interim data from the ongoing HEROIC-PKP2 Phase I/II clinical trial of LX2020 for the treatment of PKP2 arrhythmogenic cardiomyopathy. Across ten participants, including nine with at

07:37 EDT Lexeo Therapeutics (LXEO) files $300M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks

Lexeo Therapeutics, Inc. ( ($LXEO) ) just unveiled an announcement. Lexeo Therapeutics disclosed that it issued shares of its common stock in connection with a merger transaction, relying on exemptions

Lexeo Therapeutics (LXEO) announced a series of strategic transactions to expand its presence in Friedreich ataxia, including the signing of a definitive agreement to acquire Mantle Therapeutics and three new
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 15, 2027TBA | $265.14M | $-0.35 | $0.00 | 0.13 | -2.63 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.